---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041404"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:56:50.207706+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Q2 2023: cash $358M, revenue $10.4M, initiates pivotal luvelta trial, Blackstone deal

## Summary
- Cash, equivalents and marketable securities $358.3M; Vaxcyte shares valued at $33.3M; runway into H1 2025.
- Revenue $10.4M (down from $28.1M YoY); total operating expenses $56.6M (up from $47.5M).
- Initiated REFRaME Phase 2/3 pivotal study for luvelta in platinum-resistant ovarian cancer; enrollment underway.
- Received $140M upfront from Blackstone royalty monetization; eligible for up to $250M milestone payments.
- Luvelta endometrial cancer data to be presented at ESMO 2023; updated ovarian data expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-041404
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/stro-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041404
- JSON: https://secwatch.observer/filing/0000950170-23-041404.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041404.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported financial results for the second quarter of 2023.
  - Period: the second quarter of 2023
  - Result: reported results
  source text: On August 10, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.